Johnson & Johnson

News

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

Oncology

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.

News

J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.

News

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.

News

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

News

AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.